Clinical trial NCT00248534 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: methylprednisolone, temozolomide
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CSCC[C@H](N)C(O)=O
Reason stopped: 
    slow accrual/lack of resources/low priority due to combining 2 consortia
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary CNS non-Hodgkin's lymphoma by brain biopsy, positive
             cerebrospinal fluid cytology, or vitrectomy

               -  Recurrent disease

          -  Measurable disease, define as bi-dimensionally measurable lesions with clearly defined
             margins by brain MRI or CT scan

               -  Radiographical evidence of tumor progression by MRI or CT scan

               -  Steroid therapy must be stable for 5 days prior to scan

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 60-100%

        Life expectancy

          -  More than 8 weeks

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)

        Hepatic

          -  SGOT < 2 times upper limit of normal (ULN)

          -  Bilirubin < 2 times ULN

          -  No active or latent hepatitis B infection

        Renal

          -  Creatinine < 1.5 mg/dL OR

          -  Creatinine clearance ≥ 60 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No uncontrolled significant medical illness that would preclude study treatment

          -  No active infection

          -  No active HIV infection

          -  No concurrent disease that would dangerously alter drug metabolism or obscure toxicity

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  At least 7 days since prior interferon or thalidomide

          -  No concurrent prophylactic filgrastim (G-CSF)

          -  No concurrent immunotherapy

        Chemotherapy

          -  No prior temozolomide

          -  At least 14 days since prior methotrexate

          -  At least 21 days since prior procarbazine

          -  At least 42 days since prior nitrosoureas

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  See Disease Characteristics

          -  At least 7 days since prior tamoxifen

          -  No concurrent hormonal therapy

        Radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  Recovered from all prior therapy

          -  At least 28 days since prior investigational agents

          -  At least 28 days since other prior cytotoxic therapy

          -  At least 7 days since other prior non-cytotoxic agents (e.g., tretinoin)
             (radiosenitizers allowed)

          -  No other concurrent investigational drugs